Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 130

Related Citations for PubMed (Select 20145260)

1.

Pharmacokinetics and pharmacodynamics of three moxifloxacin dosage forms: implications for blinding in active-controlled cardiac repolarization studies.

Mason JW, Florian JA Jr, Garnett CE, Moon TE, Selness DS, Spaulding RR.

J Clin Pharmacol. 2010 Nov;50(11):1249-59. doi: 10.1177/0091270009356298. Epub 2010 Feb 9.

PMID:
20145260
2.

Population pharmacokinetic and concentration--QTc models for moxifloxacin: pooled analysis of 20 thorough QT studies.

Florian JA, Tornøe CW, Brundage R, Parekh A, Garnett CE.

J Clin Pharmacol. 2011 Aug;51(8):1152-62. doi: 10.1177/0091270010381498. Epub 2011 Jan 12.

PMID:
21228407
3.

Lack of effect of aprepitant or its prodrug fosaprepitant on QTc intervals in healthy subjects.

Marbury TC, Jin B, Panebianco D, Murphy MG, Sun H, Evans JK, Han TH, Constanzer ML, Dru J, Shadle CR.

Anesth Analg. 2009 Aug;109(2):418-25. doi: 10.1213/ane.0b013e3181ac1066.

PMID:
19608812
4.

Statistical characteristics of moxifloxacin-induced QTc effect.

Yan LK, Zhang J, Ng MJ, Dang Q.

J Biopharm Stat. 2010 May;20(3):497-507. doi: 10.1080/10543400903581945.

PMID:
20358432
5.

A single-dose, crossover, placebo- and moxifloxacin-controlled study to assess the effects of neratinib (HKI-272) on cardiac repolarization in healthy adult subjects.

Hug B, Abbas R, Leister C, Burns J, Sonnichsen D.

Clin Cancer Res. 2010 Aug 1;16(15):4016-23. doi: 10.1158/1078-0432.CCR-10-0280. Epub 2010 Jul 20.

6.

Application of a probabilistic method for the determination of drug-induced QT prolongation in telemetered cynomolgus monkeys: effects of moxifloxacin.

Holzgrefe HH, Cavero I, Buchanan LV, Gill MW, Durham SK.

J Pharmacol Toxicol Methods. 2007 May-Jun;55(3):227-37. Epub 2006 Sep 15.

PMID:
17097307
7.

Effects of sugammadex doses up to 32 mg/kg alone or in combination with rocuronium or vecuronium on QTc prolongation: a thorough QTc study.

de Kam PJ, van Kuijk J, Prohn M, Thomsen T, Peeters P.

Clin Drug Investig. 2010;30(9):599-611. doi: 10.2165/11537210-000000000-00000.

PMID:
20568829
8.
9.

Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study.

Matz J, Graff C, Vainio PJ, Kallio A, Højer AM, Struijk JJ, Kanters JK, Andersen MP, Toft E.

Clin Drug Investig. 2011 Nov 1;31(11):799-811. doi: 10.2165/11592950-000000000-00000.

PMID:
21967071
10.

Effects of enteral feeding on the oral bioavailability of moxifloxacin in healthy volunteers.

Burkhardt O, Stass H, Thuss U, Borner K, Welte T.

Clin Pharmacokinet. 2005;44(9):969-76.

PMID:
16122283
11.

Pharmacokinetics and tissue penetration of moxifloxacin in intervention therapy for intra-abdominal abscess.

Rink AD, Stass H, Delesen H, Kubitza D, Vestweber KH.

Clin Drug Investig. 2008;28(2):71-9.

PMID:
18211115
12.

Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects.

Démolis JL, Kubitza D, Tennezé L, Funck-Brentano C.

Clin Pharmacol Ther. 2000 Dec;68(6):658-66.

PMID:
11180026
13.

Period correction of the QTc of moxifloxacin with multiple predose baseline ECGs is the least variable of 4 methods tested.

Zhang X, Silkey M, Schumacher M, Wang L, Raval H, Caulfield JP.

J Clin Pharmacol. 2009 May;49(5):534-9. doi: 10.1177/0091270008330158. Epub 2009 Mar 13.

PMID:
19287043
14.

Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects.

Davis JD, Hackman F, Layton G, Higgins T, Sudworth D, Weissgerber G.

Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:68-75. doi: 10.1111/j.1365-2125.2008.03138.x.

15.

Sugammadex is not associated with QT/QTc prolongation: methodology aspects of an intravenous moxifloxacin-controlled thorough QT study.

de Kam PJ, van Kuijk J, Smeets J, Thomsen T, Peeters P.

Int J Clin Pharmacol Ther. 2012 Aug;50(8):595-604. doi: 10.5414/CP201693.

PMID:
22735462
16.

Electrocardiographic QTc changes due to moxifloxacin infusion.

Malik M, Hnatkova K, Schmidt A, Smetana P.

J Clin Pharmacol. 2009 Jun;49(6):674-83. doi: 10.1177/0091270008330984.

PMID:
19451404
17.

Moxifloxacin does not alter ciclosporin pharmacokinetics in transplant patients: a multiple-dose, uncontrolled, single-centre study.

Stass H, Delesen H, Kubitza D, Mai I, Bauer S, Roots I.

Clin Drug Investig. 2010;30(5):279-87. doi: 10.2165/11534310-000000000-00000.

PMID:
20384384
18.

Disposition kinetics of moxifloxacin in lactating ewes.

Goudah A.

Vet J. 2008 Nov;178(2):282-7. Epub 2007 Sep 27.

PMID:
17900948
19.

Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man.

Stass H, Kubitza D.

J Antimicrob Chemother. 1999 May;43 Suppl B:83-90.

20.

Penetration and accumulation of moxifloxacin in uterine tissue.

Stass H, Kubitza D, Aydeniz B, Wallwiener D, Halabi A, Gleiter C.

Int J Gynaecol Obstet. 2008 Aug;102(2):132-6. doi: 10.1016/j.ijgo.2008.02.020. Epub 2008 May 27.

PMID:
18501909
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk